Cleave names new VP, clinical development
This article was originally published in Scrip
Executive Summary
Cleave Biosciences has named Dr Kanya Rajangam vice-president of clinical development. Dr Rajangam will lead Cleave's ongoing clinical trials and design future studies to evaluate drug candidate CB-5083 in hematological and solid tumor malignancies, as well as advance other internally discovered compounds into development. Most recently she was executive director of the oncology and immuno-oncology program at Nektar Therapeutics. Cleave also announced that chief medical officer Dr Alessandra Cesano is leaving the company to pursue other opportunities.